HIV Protease Inhibitor Ritonavir Induces Lipoatrophy in Male Mice
- 1 December 2003
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 19 (12) , 1141-1150
- https://doi.org/10.1089/088922203771881248
Abstract
We investigated the effects of the HIV protease inhibitor ritonavir on body composition, serum lipids, and gene expression in C57BL/6 mice. Dual-energy X-ray absorptiometry measurements in ritonavir-treated male mice revealed whole-body lipoatrophy. In female mice fat reduction was restricted to the gonadal depot. A histopathological analysis showed no visible abnormalities in liver or adipose tissue from ritonavir-treated mice, although adipocytes were significantly smaller in diameter. Serum triglyceride levels were increased in ritonavir-treated male mice. Ritonavir was coadministered with the peroxisome proliferator-activated receptor α (PPARα) agonist gemfibrozil and the PPARγ agonist rosiglitazone for 8 weeks. Neither drug alleviated the hypertriglyceridemia or lipoatrophy in ritonavir-treated male mice. Rather, gemfibrozil exacerbated the lipoatrophy. Ritonavir reduced basal expression of two PPARα target genes in liver, as well as the PPARγ target gene phosphoenolpyruvate carboxykinase (PEPCK) in adipose tissues. Ritonavir partially inhibited induction of PPAR target genes by gemfibrozil and rosiglitazone. Gemfibrozil induced expression of fatty acid oxidation genes in liver, and this induction was less substantial when ritonavir was coadministered. Similarly, rosiglitazone induced expression of uncoupling protein-1, uncoupling protein-2, and PEPCK in adipose tissues, and this effect was partially inhibited by ritonavir. Thus, the effects of ritonavir on serum triglycerides and body composition may be due, at least in part, to an inhibition of PPAR function.Keywords
This publication has 45 references indexed in Scilit:
- Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment databaseAIDS, 2001
- Lipoatrophy, Fat Accumulation, and Mixed Syndrome in Protease Inhibitor???Naive HIV-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Adverse effects of antiretroviral therapyThe Lancet, 2000
- HIV Protease Inhibitor-Related Lipodystrophy SyndromeClinical Infectious Diseases, 2000
- Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance.Pharmacology & Therapeutics, 2000
- A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndromeAIDS, 2000
- Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophyThe Lancet, 1999
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS: A Nuclear Receptor Signaling Pathway in Lipid PhysiologyAnnual Review of Cell and Developmental Biology, 1996
- The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression.Proceedings of the National Academy of Sciences, 1994